- Home
- COGT vs BRSP Comparison
COGT vs BRSP Comparison
Compare COGT & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- BRSP
- Stock Information
- Founded
- COGT 2014
- BRSP 2017
- Country
- COGT United States
- BRSP United States
- Employees
- COGT 205
- BRSP N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- BRSP Real Estate Investment Trusts
- Sector
- COGT Health Care
- BRSP Real Estate
- Exchange
- COGT Nasdaq
- BRSP Nasdaq
- Market Cap
- COGT 822.0M
- BRSP 686.2M
- IPO Year
- COGT 2018
- BRSP 2018
- Fundamental
- Price
- COGT $7.23
- BRSP $5.21
- Analyst Decision
- COGT Buy
- BRSP Buy
- Analyst Count
- COGT 6
- BRSP 4
- Target Price
- COGT $15.20
- BRSP $6.83
- AVG Volume (30 Days)
- COGT 2.1M
- BRSP 486.0K
- Earning Date
- COGT 08-05-2025
- BRSP 07-29-2025
- Dividend Yield
- COGT N/A
- BRSP 12.37%
- EPS Growth
- COGT N/A
- BRSP N/A
- EPS
- COGT N/A
- BRSP N/A
- Revenue
- COGT N/A
- BRSP $340,600,000.00
- Revenue This Year
- COGT N/A
- BRSP N/A
- Revenue Next Year
- COGT N/A
- BRSP $12.19
- P/E Ratio
- COGT N/A
- BRSP N/A
- Revenue Growth
- COGT N/A
- BRSP N/A
- 52 Week Low
- COGT $3.72
- BRSP $4.16
- 52 Week High
- COGT $12.61
- BRSP $6.71
- Technical
- Relative Strength Index (RSI)
- COGT 65.40
- BRSP 51.66
- Support Level
- COGT $6.88
- BRSP $5.24
- Resistance Level
- COGT $7.83
- BRSP $5.42
- Average True Range (ATR)
- COGT 0.56
- BRSP 0.11
- MACD
- COGT 0.09
- BRSP -0.01
- Stochastic Oscillator
- COGT 78.17
- BRSP 51.14
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.